The recent description of a large amount of copy number variation (CNV) in the human genome has extended the concept of genome diversity. In this study we integrate the analysis of CNV and single nucleotide polymorphisms (SNPs) in the human CCL4L chemokine gene. CCL4L is a nonallelic copy of CCL4/MIP-1b chemokine and displays a CNV that also includes the CCL3L gene, a nonallelic copy of CCL3/MIP-1a. This CNV and two functionally relevant CCL4L SNPs (rs4796195 and rs3744595) have been recently associated to HIV pathology in three independent studies. We have quantified the CCL4L copy number and genotyped both SNPs in samples from HGDP-CEPH Diversity Panel. A strong correlation between CCL4L CNV and one of the SNPs analyzed is found, whereas no significant linkage disequilibrium is found between the two SNPs despite their close distance (647 bp), suggesting a recent appearance of the second SNP when the diversity in the first one and CNV had already been generated. The present study points out that in genes with CNV, it may be a key issue to combine the assessment of gene copy number with the genotyping of relevant SNPs to understand the phenotypic impact of genome variation in the immune response.
Introduction
Human diversity at the DNA level ranges from structural variation (such as duplications, deletions, insertions and inversions) to single nucleotide polymorphisms (SNPs). Until recently, SNPs have been the dominating type of variation explored in the human genome since it had been thought that SNPs account for much of the normal phenotypic diversity. However, the presence of copy number variation (CNV) in normal individuals has been recently reported as the major type of genetic diversity among humans, 1,2 accounting for 12% of the genome. 3, 4 CNV involves DNA fragments about 1 kb or larger and, despite their heterogeneous distribution throughout the genome, there are no large stretches of the genome exempt from CNV. 5 Nonetheless, fine sequence analyses among the members of a CNV have only been reported for very specific cases known before the CNV concept, such as color vision or immunologic functions. 6, 7 Several examples of CNV affecting genes of the immune system have been previously described (for example, a/b-defensins and FcgrIII). [7] [8] [9] From the broad HLA polymorphisms to antigen receptor diversity by recombination, molecular differences form the basis for the efficiency of the immune response. In fact, the diversity of some gene families in the immune system has become a model of molecular diversity. One of these families is the chemokine superfamily, small structurally related cytokines that have evolved to form, in humans, a complex network of proteins able to carry out many diverse immune/nonimmune and inflammatory/ homeostatic functions. 10, 11 Most, if not all, chemokines probably arose by gene duplication from a single ancestral gene and this fact is clearly reflected in the genomic organization of inflammatory chemokines: these genes are grouped in discrete chromosomal locations forming clusters and miniclusters that are considered single entities based on their overall function. 12, 13 CCL3 (MIP-1a) and CCL4 (MIP-1b) constitute, together with CCL18 (PARC), an interesting minicluster model of chemokine evolution located on chromosome 17q12. CCL3 and CCL4 genes were formed by duplication of an ancestral gene and CCL18 is an unusual large chemokine gene generated by fusion of two CCL3-like genes. 14, 15 Additionally, CCL3 and CCL4 both have a second nonallelic copy, CCL3L (LD78b) and CCL4L (LAG-1), that code for two highly similar proteins (490% identity between CCL3 and CCL3L proteins, and 495% between CCL4 and CCL4L proteins). 16, 17 CCL3L and CCL4L exhibit CNV, meaning that these genes are present in variable copy number in the human genome. 18 Regarding the CNV found in the CCL3L and CCL4L genes, it seems to have been generated by duplications of a 120 kb stretch in this region of chromosome 17 (including CCL3L, CCL4L and other nonrelated loci). 19, 20 However, two key points should be emphasized: (i) there are some individuals that lack the CCL3L-CCL4L tandem and (ii) there are haplotypes with different gene copy number (meaning that the gene copy number of both genes can be different in a single chromosome). 18 Evidence of a functional significance for the CCL3L CNV has been described by Gonzalez et al. 21 demonstrating their influence on HIV susceptibility. According to Gonzalez et al., the strength of the immune response based on CCL3L activity depends on the relative gene copy number of the individual in relation to the mean copy number of the ethnic group to which the individual belongs. This fact has two relevant implications: (i) there is a complex ethnic-specific adaptation of different factors in the immune response, and (ii) the knowledge of the population-specific variation and the worldwide distribution of copy number should be approached in order to unravel individual susceptibility and response to pathogens.
In the case of CCL4L, and in addition to the CNV, a recently described SNP (rs4796195) in the acceptor splice site of intron-2 generates a new complex splicing pattern. 19 This polymorphism creates two allelic variants: CCL4L*1, the original variant (that will be called L1) and the new described variant, CCL4L*2 (or L2 allele) which has been associated with HIV susceptibility in a casecontrol study. 19 Additionally, another SNP in the exon-2 of CCL4L gene (rs3744595) leads to a nonconservative amino-acid change (Arg22His), likely to have functional implications. These two alleles will be called R for arginine and H for histidine. Initial evidence suggest that this polymorphism can influence the survival of HIV þ patients. 22 These previous studies do not take into account the CCL4L CNV and, in fact, despite the growing interest in the identification of these CNVs and their phenotype implications to the individual structural variation found in humans, 3, 23 no data combining both types of polymorphisms is available, and the extent of independence between both types of variation (CNVs and SNPs) is still unknown.
The main aim of this study is to combine and correlate the information provided by the CNV and the SNPs in the CCL4L gene, analyzing their population structure and variation, a key factor in understanding individual immune response. We have analyzed the worldwide distribution of CCL4L copy number and genotyped two relevant SNPs determining the distribution of alleles in heterozygous multicopy samples, showing their independent structure and complexity, that cannot be ignored when analyzing the impact of chemokines in the response to pathogens.
Results
Worldwide CCL4L copy number distribution and population structure CCL4L copy number has been determined in the 1048 individuals included in the Human Genome Diversity Panel (HGDP) panel. Similar results were obtained analyzing smaller sets (H971 and H952) of individuals (data not shown). 24 Results for each individual population (mean and s.d. of CCL4L copies) are shown in Figure 1 . CCL4L copy number distribution in each population has also been determined (see Supplementary Figure 1 ). The similarity of the population CNV distribution between CCL4L and CCL3L performed in the same set of individuals is noteworthy. 21 To give a more general view of the worldwide distribution of CCL4L copy number, individuals were pooled into seven broad continental regions and the mean of CCL4L copy number was calculated. Sub-Saharan African populations display the highest number of CCL4L copies (mean ¼ 4.32 ± 0.63, including individuals with 8, 9 or 10 copies), whereas Europe present the lowest copy number (1.89 ± 0.40), including a 25% of individuals with only one CCL4L copy. The number of individuals without CCL4L gene was always below 5% in all continental regions (sub-Saharan Africa 0%, America 0%, East Asia 1.82%, Europe 2.50%, Central/South Asia 2.62%, Oceania 2.63% and Middle-East/North Africa 3.41%). CCL4L copy number distribution in each continental region has also been calculated (see Supplementary Figure 2) .
In order to test the population differentiation concerning the CCL4L copy number, the F ST statistic was calculated for the whole set of populations. A significant 0.12 (Po0.001) F ST value was found, a value very similar to the average for 67 autosomal CNVs (0.11) previously described in the four HapMap populations. 4 When an analysis of the molecular variance (AMOVA) was performed grouping the populations within the seven broad continental regions, 9.26% (Po0.001) of the variation found in the copy number was the result of differences between continental groups, and only 3.43% (Po0.001) were due to differences within continental groups. This general heterogeneity found within continental groups was significant in Asian (East Asia ¼ 4.63%, Po0.001; Central/South Asia ¼ 4.32%, P ¼ 0.004) and American (8.75%, P ¼ 0.002) populations, whereas no significant differences were found between populations within the rest of continental groups including Africa, which is noteworthy as most other genetic markers show strong heterogeneity within the African continent.
Population distribution of SNPs allelic and genotypic frequencies One of the technical challenges in analyzing SNPs within genes with CNV is the need to establish the exact number of copies for each individual, then perform the SNP genotyping and finally determine the numeric distribution of the allelic variants. The melting curves characteristic for each of the two SNPs genotyped allowed us to quantify the number of copies of each allelic variant for each individual. Figures 2a and b show the allelic discrimination in copy number for L1 and L2 variants. Analyzing the melting curve profiles in different individuals with the same ratio of allelic copies we provided evidence of the procedure reliability ( Figure 2c ). The same rationale was used to distinguish R and H variants (data not shown).
L1/L2 and R/H allelic distributions are shown in Figure 3 . L2 frequencies (Figure 3a ) range from 13% in Oceania to 43% in the Americas, being polymorphic in all the populations analyzed. On the other hand, the H frequency is very low in most of the populations analyzed, the R allele being fixed in some of the samples, and almost not present in sub-Saharan Africa and America. Concerning the population structure of these SNPs in the dataset, an F ST value of 0.04 was found for both polymorphisms (Po0.001), a smaller value than the one found for the CCL4L CNV (0.12). When the populations were grouped according to continental areas, 3.82% (Po0.001) and 3.39% (Po0.001) of the genetic variation for the L1/L2 and the R/H alleles, respectively, was due to differences between continental regions. Nevertheless, the genetic heterogeneity within continents was very low and only significant in sub-Saharan Africa (3.51%, P ¼ 0.002) and Oceania (8.29%, P ¼ 0.043) for the L1/L2 polymorphism, and in America (1.94%, P ¼ 0.029) for the R/H polymorphism.
The genotypic frequencies were also calculated considering that, in the case of genes with CNV, what is usually called 'heterozygous' are those that present the two allelic variants in their genome regardless of their copy number ( Figure 4) . A relevant aspect is that in genes with CNV the relationship between allelic and genotypic frequencies do not necessarily maintain the HardyWeinberg equilibrium (HWE) due to the unbalanced distribution of SNP variants among different copies of the gene in the same chromosome. For L1/L2 genotypes, the detailed frequencies for each genotype in individual populations and continental regions are shown in Figure 4a . Interestingly, whereas the maximum heterozygosity frequency expected following the HWE is 50%, there are three continental regions that show a frequency over 50%: East Asia (66%), sub-Saharan Africa (85%) and America (86%), including specific populations of subSaharan Africa and America with heterozygosity values over 90%. On the other hand, R/H genotypes for continental regions follow the HWE except for the Oceanic populations ( Figure 4b ).
Correlation between CNV and SNPs in the CCL4L gene To better define the relationship between CNV and SNPs in the CCL4L gene, we analyzed the correlation between the CCL4L copy number and the frequencies of the two analyzed SNPs using two different approaches: (a) CCL4L copy number versus minor allele frequency and (b) CCL4L copy number versus heterozygous frequency ( Figure 5 ). For the L1/L2 copies, there is a strong correlation between CCL4L copy number and allelic and heterozygous frequency (R ¼ 0.731, Po0.0001 and R ¼ 0.890, Po0.0001, respectively), pointing to a common evolutionary history of these polymorphisms. For the R/H copies, a small negative correlation between CCL4L copy number and allelic frequency (R ¼ À0.491, P ¼ 0.0002) and a lack of correlation between CNV and heterozygous frequency (R ¼ À0.186, P ¼ 0.190) were found, suggesting that these two kinds of polymorphisms arose independently.
The opposite results of the two analyzed SNPs regarding to CCL4L CNV are in agreement with the lack of linkage disequilibrium (LD) between them (r 2 ¼ 0.0185; P ¼ 0.097), which has been calculated using data of individuals with one CCL4L copy (n ¼ 149). The haplotypes found in these set of individuals consisted of 111 L1/R copies, 26 L2/R copies and 12 L1/H copies. No L2/H copies were found in the set analyzed. The lack of LD between both SNPs, which are at 647 bp distance, and the lack of correlation between CNV and R/H copies are noteworthy.
Discussion
The study of the functional implications of genetic diversity has generated a large amount of data involving SNPs in many pathologies as well as in nonpathological processes. [25] [26] [27] Recently, the widespread presence of CNVs in the genomes of healthy individuals with no obvious genetic disorders has been described in a few populations, 1,2 but relatively few data has been reported regarding CNVs and disease resistance or susceptibility. 9, 21 Regarding this point, the main aim of our work was to link the analysis of SNPs and CNVs within a worldwide framework to achieve a more powerful tool in the future determination of genetic basis of susceptibility or resistance to disease. It seems clear that genes with CNV require a nonconventional method to study their SNPs, and this is the reason why we established a clear and precise approach to solve this problem. We focused on the CCL4L gene, which provides one of the best examples of CNV in the human immune system (CCL4L copies in our population set range from 0 to 10) combined with the presence of interesting SNPs (rs4796195 and rs3744595 both related with HIV pathology) and the study was carried out in a large set of populations to provide a global idea of the contribution of each element and to detect the possible interactions between them. The knowledge of the intra-and interpopulation variation seems to be the key parameter in understanding the individual chemokine immune response, beyond the knowledge of the individual genetic composition. 21 The CNV analyzed in this study belongs to the multiallelic CNVs (see CNV classification in Redon et al.
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) and extends across a 120 kb stretch in the q12 region of chromosome 17 that includes CCL4L and CCL3L genes. The high level of similarity between them, common gene strand orientations, comparable intergenic distances and amino-acid similarities strongly argue for nonallelic recombination as a mechanism responsible for the origin of one of these gene pairs. 20 Complex patterns of CNV have been described at sites of segmental duplications with several genes involved in the repeated segment. 28, 29 To date, CCL4L and CCL3L are the only chemokine genes that are present in the human population at variable number of copies. Interestingly, while there are often equivalent numbers of CCL3L and CCL4L genes, there are some exceptions suggesting that these genes are not simply coduplicated. Recently, Gonzalez et al. 21 quantified the CCL3L copy number in the same individual cohort (HGDP) and, although the CCL3L raw data is not available for comparison, CCL4L results are highly concordant, although a slight lower copy average of CCL4L gene is found compared to CCL3L in all populations and continental regions. This correlation between CCL4L and CCL3L copies suggests the involvement of both genes in HIV susceptibility. The lower average of CCL4L copies found in the present analysis is in agreement with the results of Towson et al., 18 who quantified the CCL3L and CCL4L gene copies in 100 individuals of European ancestry, showing 60% of samples with equal number of CCL3L and CCL4L genes, 33% having more CCL3L copies compared with CCL4L (generally one or two copies more) and only a 7% of samples having more CCL4L copies. All these results support the presence of a single unit containing only one of these genes and also being susceptible to duplication. Thus, the consideration of both genes as a single repeat unit is an oversimplification, as it is also the consideration of the raw number of repeats in the CCL4L region. This additional complexity found in the CCL3L-CCL4L CNV implies that it is necessary to check if all the genes spread through a region with CNV are the result of a single duplication/deletion process.
The CCL4L CNV described shows a clear population differentiation, similar to that previously found on 67 autosomal CNVs with the HapMap samples. Besides this continental differentiation in CNV, Asian and Amerindian populations exhibit a genetic heterogeneity in copy number whereas the rest of the continental groups are genetically homogeneous, including Africans. It is noteworthy that the CCL4L genetic differentiation between populations is three times larger in CNV (F ST ¼ 0.12) than in the SNPs analyzed (F ST ¼ 0.04).
Thus, the population differentiation in relation to SNP frequencies within the CCL4L copies is more homogeneous between and within continental regions than CNV. This result suggests that the analysis of CNV might be more informative in unraveling population genetic relationships than SNP variation but it does not allow a direct functional correlation. Moreover, it suggests complex dynamics in the region as it cannot be explained as a variation in the number of copies of pre-existing different units defined by their nucleotide composition.
With regard to the SNP analysis, despite the relatively short distance between them (647 bp), they are not in LD and their worldwide distribution is very different. The low frequency of the H allele worldwide, the absence of L2/H haplotypes, and the lack of correlation between R/H polymorphism and CNV suggests that the H allele appeared recently in a L1 copy background. Our results are compatible with the appearance of the allele H once the L1/L2 diversity was already established. This would imply that the H variant is completely associated with the L1 copy where it was generated, splitting L1 into two lineages: L1H and L1R. This fact would explain why the H variant does not correlate either with CNV or with the L1/L2 variation despite the short distance between both SNPs. It is also interesting to note the near absence of the H variant in sub-Saharan African samples, which reinforces the idea of the recent appearance of the H allele in human populations.
Association studies have focused primarily on SNP genotyping. However, it is important to determine whether CNVs are in LD with common SNPs, and thus if CNV could be assessed indirectly in SNP-based studies. Regarding this question, although it has been shown that small indels and surrounding SNPs are in LD in the human genome, 30 Redon et al. 4 found that diploid copy number of multi-allelic CNVs is poorly predicted by neighboring SNPs. Interestingly, among the populations included in this study the L1/L2 variants (located inside the CNV) have a high correlation with the CCL4L copy number, and, therefore, these variants could be used as a proxy of CCL4L copies of a given population. The possibility to determine the copy number of a gene or group of genes through the genotyping of a SNP is an attractive approach since, to date, SNP genotyping is an easier and simpler methodology than copy number determination.
As previously mentioned, the three CCL4L genetic variation elements (the CCL4L CNV and both the SNPs analyzed) are involved in HIV pathology. However, each of them was analyzed independently in previous studies and it would be relevant to determine the specific contribution of each one in susceptibility/resistance to HIV. Data of our study revealed that sub-Saharan African and Amerindian populations display the highest number of CCL4L (and CCL3L) copies (described as a HIV resistance factor) 21 but, at the same time, showed also the highest frequency of the L2 allele (described as a HIV susceptibility factor). 19 Conversely, the European populations display the lowest number of CCL4L-CCL3L copies and also a low frequency of L2 allele. Additionally, the lack of correlation of the R/H variants with CCL4L copy number increases the complexity in the interpretation of the role of these three elements. Next to the competing effects reported, the balance between presenting a high or low number of CCL4L-CCL3L copies (compared to the population distribution) and the L1/L2 allele frequencies, together with all the other HIV susceptibility/resistance described factors (including the rs3744595 SNP role in survival of HIV þ patients), could determine the final genetic background related to the disease susceptibility.
In genes with CNV it is important to combine the assessment of gene copy number with the genotyping of relevant SNPs and it should now become standard in the design of all studies of the genetic basis of phenotypic variation, in particular in studies of resistance/susceptibility to disease. Moreover, the population variation is, in some cases, a key factor to understand the individual susceptibility. We envisage that this integrated analysis will result in a better comprehension of these two most important genetic variability generating mechanisms.
Materials and methods

Samples
A total of 1064 individuals from 52 worldwide populations included in HGDP 31 were analyzed for the CCL4L copy number determination and genotyped for the SNPs selected. From the original panel, several duplicated samples were used as internal controls and some atypical individuals were ignored. The panel used is the H1048 according to Rosenberg et al. 24 which includes 1048 individuals. For some of the analyses, individuals were pooled into seven broad continental regions: subSaharan Africa (SSAFR), Middle East/North Africa (MENA), Europe (EUR), Central/South Asia (CSASIA), East Asia (EASIA), Oceania (OCE) and America (AME).
CCL4L copy number determination CCL4L copy number determination was performed by using real-time PCR in an ABI PRISM Sequence Detection System 7900 Instrument (Applied Biosystems, Foster City, USA). Using the Custom Taqman Gene Expression Assay Service (Applied Biosystems), a mix of unlabeled PCR primers and a TaqMan MGB probe, FAM dye labeled was designed to amplify specifically CCL4L and clearly discriminate CCL4L from CCL4. Primers and probe sequences are as follows: sense primer (located at intron 2) 5 0 -CATGGTCAGGCAGAGGAA-GATG-3 0 ; antisense primer (located at exon 3) 5 0 -GCTTGCCTCTTTTGGTTTGGAAT-3 0 ; probe (located at intron 2, in a region that is deleted in CCL4) 5 0 -TACCACAGGCAAGGGAT-3 0 (FAM labeled). As a control, TaqMan RNaseP Control (Applied Biosystems) was used following the supplier's recommendations. The amplification protocol for this reaction was 10 min of initial setup at 95 1C, followed by 40 amplification cycles (15 s of denaturation at 95 1C and 60 s of annealing/ extension at 60 1C). For each sample, amplification of the target gene (CCL4L) and a control gene (RNaseP, that has two copies per diploid human genome) was performed in the same well (multiplex format) and by duplicate. To generate standard curves, we used six serial 1:2 dilutions (146.4-4.57 ng) of genomic DNA from CEM cells (known to have two copies of CCL4L per diploid genome as proved by Southern blot densitometry). 18 Each standard curve dilution was run in triplicate in each PCR plate (384 wells) for CCL4L and RNaseP using the primers and probes described above (multiplex). The square of the Pearson's correlation coefficient (R 2 ) for a standard curve was 40.97 (in case of lower value, samples would have been repeated, although in our hands this situation was not encountered). Threshold cycle (C T ), the cycle number at which the fluorescence reaches a fixed threshold, of each sample was determined and converted into template quantity using the standard curves. Copy number was established as the ratio of the template quantity for CCL4L to the template quantity for RNaseP, multiplied by two. Average copy number of duplicates was calculated based on the ratio between the sample and the RNaseP single locus control. We also calculated the s.d. and what percentage represented the s.d. with reference to the average, accepting only values o10% (in case of greater differences, quantification of samples was repeated). Once all these steps were successfully done, we assigned a real number of copies to each sample (see Supplementary Figure 3 showing examples of the quantification procedure). We established a difference of ±0.25 as the threshold to consider a result as a real number of copies (for example, a final number of 2.20 or 1.80 copies is considered as two real copies). This value, according to the distribution found, is very conservative, with a negligible number of cases out of the established range. When the final number exceeded the established threshold, the quantification of the sample was repeated.
CCL4L SNPs genotyping CCL4L genotyping for rs4796195 and rs3744595 SNPs was performed using real-time PCR with fluorescence resonance energy transfer (FRET) probes in a LightCycler Instrument (Roche, Mannheim, Germany). For each SNP we used a pair of specific primers for the CCL4L region where the SNP is located and a pair of FRET probes. Primers and probes sequences for rs4796195 SNP are as follows: sense primer (located at intron 2) 5 0 -GCAGAG GAAGATGCCTACCAC-3 0 ; antisense primer (located at exon 3) 5 0 -CTGAGTATGGAGGAGATGCGG-3 0 ; anchor fluorescein-labeled probe (located at exon 3) 5 0 -AGCG CAGACTTGCTTGCCTCTTTT-3 0 ; sensor LC-Red705-labeled probe (located at intron 2/exon 3 junction) 5 0 -TTTGGAATCCGTAGAACAAGG-3 0 . Primers and probes sequences for rs3744595 SNP are as follows: sense primer (located at intron 1) 5 0 -GGAATGGATACAAGGGACCA-3 0 ; antisense primer (located at intron 2) 5 0 -CAGC CAGGGGTTGATACTC-3 0 ; anchor fluorescein-labeled probe (located at exon 2) 5 0 -CAGAGGCTGCTGGTCT CATAGTAATCT-3 0 ; sensor LC-Red610-labeled probe (located at exon 2) 5 0 -CCACAAAGTTGCGAGGAA-3 0 . PCR reaction was performed in a final volume of 10 ml; the reaction mixture contained 1 ml of LightCycler FastStart DNA Master HybProbe, 1 mM primer sense, 0.2 mM primer antisense and 0.2 mM each of hybridization probe (anchor and sensor), 2 mM of MgCl 2 and 2 ml of template DNA (the amount of DNA added to each PCR reaction was between 10 and 20 ng). The amplification protocol for these reactions was: 10 min of initial denaturation and activation of the FastStart enzyme at Numerical allelic discrimination in heterozygous individuals for rs4796195 and rs3744595 SNPs When two allelic variants are detected during the SNP genotyping process, it is not straightforward, except in cases of two CCL4L copies, to determine how many CCL4L copies present each allelic variant. To assess the exact number of CCL4L copies to each allelic variant in heterozygous samples with more than two CCL4L copies, we used the melting curves produced by FRET probes. Using the chart that plots the first negative derivative of the sample fluorescent curves, the melting temperature of each sample appears as a peak. Displaying the melting temperatures as peaks makes it easier to distinguish each sample's characteristic melting profile and to discern differences between samples. Our genotyping analysis result data included each sample's melting temperature and also the size of the area under each sample's melting peak. For each SNP, each allelic variant showed a characteristic Tm: for SNP rs4796195, the L1 and L2 variants show a Tm of 53 ± 0.5 and 62 ± 0.5 1C, respectively, whereas for the SNP rs3744595, the R (arginine) and H (histidine) variants showed a Tm of 55.5 ± 0.5 and 48±0.5 1C, respectively. In case of heterozygous samples, after total CCL4L copy number quantification, the ratio between the areas' peaks allowed us to ascribe the exact number of CCL4L copies to each allelic variant.
Statistical analysis
Datasets were analyzed using Sigmastats software. When necessary, the results were expressed as the mean value ± s.d. A Pearson correlation test was applied to the datasets to determine statistically significant correlation differences.
In order to assess the population structure, F ST values based on the individual CNV were calculated with the ARLEQUIN package version 2.000. 32 In order to apportion the fraction of the genetic variance due to differences between and within continental groups, several AMO-VA 33 were performed also using Arlequin. AMOVA was performed both for the whole population set and for each of the seven continental groups previously defined.
LD between rs4796195 and rs3744595 SNPs was measured with D 0 and R 2 parameters with the Haploview software. Since CNV did not allow us to phase unambiguously the alleles of both SNPs, LD was calculated taking into account the 149 individuals who exhibit a single copy of CCL4L.
